Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

- - - - 85.2 85.2 Total operating expenses 2,316.0 (135.1) (16.9) (30.8) - 2,133.2 Operating income 805.2 135.1 16.9 30.8 - 988.0 Interest income 1.5 - - - - 1.5 Interest expense (28.8) - - - - (28.8) Other income/(expense), net 15.9 2.4 - (23.5) - (5.2) Total other expense, net (11.4) 2.4 - (23.5) - (32.5) Income before income taxes and equity in earnings of equity method investees 793.8 137.5 16.9 7.3 - 955.5 Income taxes (187.3) (35.6) (4.2) 4.5 (222.6) Equity in earnings of equity method investees, net of tax 3.2 - - - - 3.2 Net income 609.7 101.9 12.7 11.8 - 736.1 Impact of convertible debt, net of tax 25.2 - - - - 25.2 Numerator for diluted EPS 634.9 101.9 12.7 11.8 - 761.3 Weighted average number of shares (millions) - diluted 595.0 - - - - 595.0 Diluted earnings per ADS 320.1c 51.4c 6.4c 5.9c - 383.8c

The following items are included in Adjustments:

a)Amortization and asset impairments: Impairment of intangible assets ($16.0 million), amortization of intangible assets relating to intellectual property rights acquired ($119.1 million), impairment of available for sale securities ($2.4 million), and tax effect of adjustments;

b)Acquisitions and integration activities: Unwind of ABH inventory step-up ($9.0 million), costs associated with acquisition and integration of ABH ($10.5 million) and integration of Movetis ($5.6 million), less adjustment to contingent consideration payable for EQUASYM ($8.2 million), and tax effect of adjustments;

c)Divestments, reorganizations and discontinued operations: Accelerated depreciation ($6.6 million) and dual running costs ($2.4 million) on the transfer of manufacturing from Owings Mills to a third party, re-measurement of DAYTRANA contingent consideration to fair value ($3.8 million), reorganization costs ($18.0 million) on the transfer of manufacturing from Owings Mills to a third party and the establishment of an international commercial hub in Switzerland,
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015   GenoSpace , ... the interpretation and analysis of genomic and other ... has joined the company as Vice President ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners ... integrate, interpret, analyze and explore complex sets of ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading ... clinical study of its canine osteoarthritis stem cell product, currently under development for ... KS) and will be marketed in the US by Aratana. This product, termed ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/30/2015)... NH (PRWEB) , ... July 30, 2015 , ... ... homogenizer for advanced fluid applications and designed for continuous operation up to 1500 ... and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... 2011 Conducting genetic profiles using microRNA can help ... also develop brain metastasis (BM), according to a study ... Research Institute (TGen). The study identified microRNA-328 as ... the spread of cancer to the brain in patients ...
... N.J., April 1, 2011 Ethicon, Inc., announced today ... treated with BIOPATCH® Protective Disk with CHG as part ... risk of intravascular catheter-associated infections in the United States. ... dressing is designated as a Category 1B recommendation. BIOPATCH® ...
... by Carnegie Mellon University chemist Krzysztof Matyjaszewski are using ... polymerization (ATRP), a widely used method of creating industrial ... 1 issue of Science , represents a breakthrough ... the ATRP process, which will allow for the creation ...
Cached Biology Technology:TGen and Scottsdale Healthcare researchers discover microRNA role in brain metastasis 2New CDC Guidelines for Prevention of Intravascular Catheter-Associated Infections Designate Chlorhexidine Gluconate-Impregnated Sponge as a Category 1B Recommendation Exclusively Based on Evidence Related to BIOPATCH® Protective Disk With CHG 2New CDC Guidelines for Prevention of Intravascular Catheter-Associated Infections Designate Chlorhexidine Gluconate-Impregnated Sponge as a Category 1B Recommendation Exclusively Based on Evidence Related to BIOPATCH® Protective Disk With CHG 3Carnegie Mellon researchers electrify polymerization 2Carnegie Mellon researchers electrify polymerization 3
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... DUBLIN , June 30, 2015 ... ) has announced the addition of the ... their offering. To this date, fingerprint ... biometric technology and fingerprint sensors are well developed. ... capacitive sensing technology. The domain of ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... study of apex predators in the Pacific Ocean found ... previously thought, unknown relationships between other species, and the ... of these sea creatures. The field program, dubbed ... at 23 species from 2000-09 and included researchers from ...
... WI, JUNE 22, 2011 -- Vinyl chloride is a ... anaerobic conditions. These solvents are used in many industrial ... most encountered groundwater pollutants in industrialized countries. Groundwater is ... to determine if vinyl chloride can be further degraded ...
... by psychologists at the University of Toronto and Tufts University ... sexual orientation when looking at his face, when she is ... thoughts or a mating goal heightens a woman,s ability to ... not apparent when a woman is judging another female,s orientation," ...
Cached Biology News:Decade-long study of Pacific predators shows importance of biological 'hotspots' 2Decade-long study of Pacific predators shows importance of biological 'hotspots' 3Psychologists find link between ovulation and women's ability to identify heterosexual men 2
... to reward the animal for foraging behavior.The Spatial ... built around a video camera, frame grabber, and ... fields at once and up to 6 moving ... records them, but also allows video replay of ...
... Feature Extraction Software reads and ... to prepare microarray data for ... * one 1-year license ... NFP/Academic accounts ,one CD-ROM containing ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... DW4 liquid handling system from Molecular Devices ... in one instrument. The system handles a ... plate washing96-, 384- and 1536-welland is the ... DW4 has been optimized to dispense from ...
Biology Products: